Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

360 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study.
Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. Gerstein HC, et al. Diabet Med. 2006 Jul;23(7):736-42. doi: 10.1111/j.1464-5491.2006.01881.x. Diabet Med. 2006. PMID: 16842477 Clinical Trial.
Dysglycaemia and risk of cardiovascular disease.
Gerstein HC, Yusuf S. Gerstein HC, et al. Lancet. 1996 Apr 6;347(9006):949-50. doi: 10.1016/s0140-6736(96)91420-8. Lancet. 1996. PMID: 8598762 No abstract available.
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.
Gerstein HC, Bosch J, Pogue J, Taylor DW, Zinman B, Yusuf S. Gerstein HC, et al. Diabetes Care. 1996 Nov;19(11):1225-8. doi: 10.2337/diacare.19.11.1225. Diabetes Care. 1996. PMID: 8908384 Clinical Trial.
Dysglycaemia: a cardiovascular risk factor.
Gerstein HC. Gerstein HC. Diabetes Res Clin Pract. 1998 Jul;40 Suppl:S9-14. doi: 10.1016/s0168-8227(98)00036-9. Diabetes Res Clin Pract. 1998. PMID: 9740496 Review.
360 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page